NETRF Board of Scientific Advisors

The Board of Scientific Advisors provides scientific direction to the Neuroendocrine Tumor Research Foundation (NETRF) by offering advice, conducting peer-review of grant proposals, and serving as leaders in the field. The Board of Scientific Advisors comprises highly distinguished medical leaders who share a commitment to discovering a cure for neuroendocrine cancer. All members of the Board of Scientific Advisors are recognized experts in medical research, published authors in the top peer-reviewed medical journals, and leaders of collaborative research projects at top-ranked universities and institutes.

Board of Scientific Advisors

Daniel Chung, MD

Co-Chair

Clinical Chief, Gastrointestinal Unit, Massachusetts General Hospital; Director, High-Risk GI Cancer Clinic

Board Certification: Gastroenterology
Education: Harvard Medical School (MD)
Residency: Massachusetts General Hospital
Fellowship: Massachusetts General Hospital

George Fisher, MD, PhD 

Co-Chair

Colleen Haas Chair in the School of Medicine Gastroenterology, Stanford Medical School

Board Certification: Medical Oncology
Education: Stanford University (MD and PhD)
Residency: Stanford University Medical Center
Fellowships: Stanford University Medical Center

Lisa Bodei, MD, PhD

Director, Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center

Board Certification: Nuclear Medicine
Education: University of Pisa (MD); University of Groningen (PhD)
Residency: University of Pisa (Italy)
Fellowship: European Institute of Oncology (Italy)

David Lee, PhD

Senior Director, Analytical Chemistry, Mersana Therapeutics; Adjunct Associate Professor of Chemistry at Northeastern University

Education: Scripps Research Institute (PhD)
Postdoctoral Fellowship: Whitehead Institute

Andrew Leiter, MD,  PhD

Professor, University of Massachusetts Medical School

Board Certification: Gastroenterology, Internal Medicine
Education: Case Western Reserve University (MD and PhD)
Residency: University Hospital of Boston
Fellowship: New England Medical Center

Rustgi

Anil Rustgi, MD

Director, Herbert Irving Comprehensive Cancer Center at Columbia University. 

Board Certification: Internal Medicine
Education: Yale University (MD)
Residency: Harvard Medical School, Beth Israel Deaconess Medical Center
Fellowship: Massachusetts General Hospital

Ramesh Shivdasani, MD, PhD

Physician, Dana-Farber Cancer Institute; Professor, Harvard Medical School

Board Certification: Medical Oncology
Education: University of Michigan (MD and PhD)
Fellowship: Dana-Farber Cancer Institute
Residency: Brigham and Women’s Hospital

Chrissie Thirlwell, MD, PhD

Senior Lecturer and Consultant in Medical Oncology, Royal Free Hospital NET Unit and University College London Cancer Institute, University College London

Education: University College London (MD); University of London (PhD)
Post-Graduate Training: St. Bartholomew’s Hospital, Chelsea and Westminster, Charing Cross, Hammersmith and University College London Hospitals

Dung Thi Le, MD

Associate Professor of Oncology, Johns Hopkins University School of Medicine; Physician, Johns Hopkins Kimmel Cancer Center

Board Certification: Medical Oncology
Education: Johns Hopkins University School of Medicine (MD)
Residency: Johns Hopkins University School of Medicine
Fellowships: Johns Hopkins University School of Medicine

Evan Vosburgh, MD

Associate Clinical Professor of Medicine, Yale University School of Medicine and at Robert Wood Johnson Medical School

Board Certifications: Medical Oncology, Hematology
Education: Albany Medical College (MD)
Residencies: Albany Medical Center
Fellowship: Boston University School of Medicine

Emeritus Members

  • Arnold Levine, PhD, Simons Center for Systems Biology at the Institute for Advanced Study
  • Thomas J. Lynch Jr., MD, Chief Scientific Officer, Bristol Meyers Squibb
  • William Sellers, MD, Broad Institute